Podcast: ESMO26: Major readouts from the 2026 congress
This year's European Society of Medical Oncology (ESMO) Congress has come to a close, with hundreds of studies having been…
Oncology
-
-
ESMO26: Standard dosing prevails over 12-week checkpoint inhibitors in MOIO trial
At the 2026 European Society for Medical Oncology (ESMO) Congress, investigators presented interim data from the Phase III MOIO study,…
-
ESMO26: KEYNOTE-C93 backs chemo-free Keytruda in dMMR endometrial cancer
Mismatch repair-deficient (dMMR) endometrial cancer is among the most immunotherapy-sensitive solid tumours. Yet first-line treatment typically pairs immunotherapy with carboplatin…
-
ESMO26: SANOVO data backs 1L Orpathys use in NSCLC subgroup, but AEs temper reaction
Results of two Phase III trials, SANOVO and SAFFRON, with HUTCHMED and AstraZeneca’s Orpathys (savolitinib) were presented recently at the…
-
ESMO26: Bayer’s Phase III Nubeqa win leaves survival and abiraterone questions open
Approximately 15% of men with very high-risk prostate cancer develop incurable distant metastases within five years of definitive treatment. Standard…
-
ESMO26: GSK’s Mo-Rez seeks an edge in a crowded ADC field in ovarian cancer
For GSK’s mocertatug rezetecan (Mo-Rez), the tumour microenvironment may predict response better than the target itself. B7-H4 has emerged as…
-
AstraZeneca deepens Summit ties on ADC-bispecific cancer combo testing pact
AstraZeneca and Daiichi Sankyo have partnered with Summit Therapeutics to explore the potential of their co-developed antibody-drug conjugate (ADC), Datroway…
-
Kyowa Kirin, Knight agree Latin American distribution deal for mogamulizumab
Kyowa Kirin’s wholly owned subsidiary Kyowa Kirin International has signed an exclusive distribution agreement with Knight Therapeutics for Poteligeo (mogamulizumab)…
-
Daiichi Sankyo, MSD withdraw cancer drug application
Daiichi Sankyo and Merck & Co (MSD) have voluntarily withdrawn their biologics license application (BLA) for ifinatamab deruxtecan, aimed at…
-
Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion
Bayer has landed an accelerated US approval for its non-small cell lung cancer (NSCLC) therapy, Hyrnuo (sevabertinib), expanding the drug’s…
